PBE vs. RSPH: Is a Biotech ETF or Equal-Weight Healthcare ETF the Better Choice for Investors?
PBE offers higher income and stronger returns, while RSPH provides broader diversification with lower costs and drawdown risk.
Overview
Healthcare investors often choose between targeting high-growth sub-sectors or capturing the broader market.
The Invesco Biotechnology & Genome ETF (NYSEMKT:PBE) provides a concentrated approach to the biotech industry, while the Invesco S&P 500 Equal Weight Health Care ETF (NYSEMKT:RSPH) offers broader exposure with lower volatility. Here's how the two compare on the most important factors for investors.
Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield.
Details
Source
Originally published at www.fool.com.